CDNF (Cerebral Dopamine Neurotrophic Factor) belongs to a new family of NF, which 31 presents several beneficial activities beyond the brain. Little is known about CDNF in the 32 cardiac context. Herein we investigate CDNF effects in cardiomyocytes under endoplasmic 33 reticulum (ER)-stress and in whole rat hearts subjected to ischemia/reperfusion (I/R). We 34 showed that CDNF is secreted by cardiomyocytes stressed by thapsigargin and by isolated 35 hearts subjected to I/R. CDNF protects human and mouse cardiomyocytes against ER-stress 36 by restoring the calcium transient, and isolated heart against I/R injuries by reducing the 37 infarct area and avoiding mitochondrial impairment. This protection is abrogated by 38 wortmannin (PI3K-inhibitor) or by heptapeptides containing KDEL sequence, which block 39 KDEL-receptor. These data suggest that CDNF induces cardioprotection via KDEL receptor 40 binding and PI3K/AKT activation. This is the first study to propose CDNF as a cardiomyokine 41 and to unravel the receptor and signaling pathway for this interesting family of NF. 42
receptors (KDEL-R). This sequence is present in several ER/SR-resident proteins such as 76 GRP78 (glucose-regulated protein 78), calreticulin and PDI (protein disulfide isomerase) 77 (Raykhel et al., 2007; Capitani et al., 2009 ), for instance. The KDEL-R is involved in the 78 retrieval of proteins from Golgi back to ER/SR, avoiding their secretion. The presence of 79 degenerated KDEL sequences in MANF and CDNF suggests that their affinity for KDEL-R is 80 diminished, which contributes to their increased secretion (Glembotski et al., 2012) . Indeed, 81 deletion of the RTDL sequence from MANF enhances its secretion in mouse mesencephalic 82 astrocytes, suggesting that MANF-KDEL-R interaction in the ER/SR compartment regulates 83 MANF secretion (Oh-Hashi et al., 2012) . 84
The cardioprotective activity of MANF has been investigated in detail (Tadimalla et 85 al., 2008; Glembotski et al., 2011; Glembotski et al., 2012) , but even though the heart and 86 skeletal muscle express relatively high amounts of CDNF (Lindholm et al., 2007) , there is 87 only one report in the literature showing increased levels of CDNF expression in ER/SR 88 stressed cells. Tunicamycin (TN), an ER/SR stressor, raised the expression of CDNF in H9C2 89 cells, a rat cardiomyoblast cell line, while a CDNF-hemagglutinin construct enhanced 90 resistance of cardiomyocytes to TN, reducing apoptosis (Liu et al., 2018) . However, the 91 authors investigated neither the mechanism of action of CDNF nor its role to cardiac 92
functions. 93
The main goal of the present study was to investigate CDNF effects in 94 cardiomyocytes. By using isolated hearts from rats and cell culture of cardiomyocytes from 95 mice as well as human induced pluripotent stem cells differentiated into cardiomyocytes 96 (hiPSC-dCM), we show that CDNF is secreted by cardiomyocytes when calcium stores are 97 disturbed by thapsigargin (TG), an ER stressor, and in isolated hearts subjected to 98 ischemia/reperfusion (I/R). Exogenously added CDNF protects the heart against the injuries 99 induced by I/R or TG and this protection is abrogated in the presence of wortmannin, a PI3K-100 specific inhibitor, or by KDEL-containing heptapeptides, suggesting that the PI3K/AKT 101 pathway is involved in CDNF-induced cardioprotection and the KDEL-R is a receptor for 102 CDNF in the cardiac context. Results 104
Thapsigargin (TG) induces ER stress and increases CDNF secretion in neonatal ventricular 105
cardiomyocytes and in human induced pluripotent stem cells differentiated into 106 cardiomyocytes (hiPSC-dCM) 107 their differentiation was confirmed by expression of troponin T (TnT) . Approximately 61% of 109
TnT-positive cells were observed in our differentiation protocol (not shown). As seen in 110 Figure 1, in the absence of TG, CDNF was found mainly inside the cells (panels A and C, 111 controls) and very little of this NF appeared in the cell media (panels B and D, controls) . 112
However, after 20h in the presence of TG, there was an increase in the amount of CDNF 113 detected in the cell lysates (panels A and C, TG), and considerable amounts were also 114 detected in the cell media (panels B and D, TG). As seen in Figure 1E , treatment with TG 115 (1µmol/L/20h) significantly increased the expression of GRP78 to 1.7-fold when compared to 116 controls, confirming that these cells were under ER/SR stress condition. Interestingly, when 117 the cells were pre-treated with 1µmol/L exogenous CDNF (exoCDNF) for 15min before TG 118 addition, there was no increase in GRP78 (panel E), a marker of ER stress, suggesting that 119 exoCDNF is preventing TG-induced ER/SR stress. Figure 1G shows that isolated hearts 120 subjected to I/R had their levels of CDNF increased to 27 times the control values, and this 121 was accompanied by an increase in CHOP (CCAAT/-enhancer-binding protein homologous 122 protein), another ER/SR stress marker, to ~1.7-fold, suggesting that these hearts were under 123 ER/SR stress. ExoCDNF added before I/R led to a significant decrease in CHOP levels by 124 approximately 50% (Figure 1F) . 125
Taken together these data suggest that TG and I/R, two ER/SR stressors, increase the 126 concentration of CDNF, GRP78 and CHOP in hiPSC-dCM and neonatal mice cardiomyocytes 127 as well as in the intact heart. Pre-treatment of the cells or the hearts with exoCDNF blocked 128 the increase in the two UPR markers, GRP78 and CHOP, suggesting that CDNF is an anti-129 cytosolic calcium overload (Figure 2) . The addition of wortmannin abrogates the effects of 140 CDNF on calcium transients after TG addition (to be described later). 141
Cardioprotective effects of exoCDNF on isolated hearts 142
Initially, we evaluated whether rat heart chambers could express endogenous CDNF in 143 significant amounts. As shown in Figure 3 this does occur with the ventricles expressing 144 greater amounts of CDNF per unit of total protein than the atria. 145
Next, the cardioprotective activity of CDNF was evaluated by perfusion with exoCDNF 146 as a preconditioning treatment (Figure 4 A and B) , and as a postconditioning treatment 147 (Figure 4 C and D) . Since there was no significant difference in the baseline of the left 148 ventricular developed pressure (LVDP) among the groups (Table 1) , all LVDP changes are 149 expressed as percentage of the baseline values, which were taken as 100%. Under ischemic 150 condition all control hearts exhibited a rapid reduction of LVDP down to zero, recovering 151 poorly (~20%) during reperfusion (panels A and C, circles). Interestingly, preCDNF and 152 postCDNF treatments enhanced these recoveries considerably, up to 70% and 50%, 153 respectively (panels A and C, squares). Regarding left ventricular end-diastolic pressure 154 (LVEDP; panels B and D), preCDNF kept the pressure low during perfusion (40 mmHg, 155 squares) in relation to the control, which rose to ~70 mmHg at the end of the reperfusion 156 process (circles). However, postCDNF treatment presented no significant alteration in LVEDP 157 compared to control (panel D). 158
Myocardial infarct areas evaluated after 60 min of reperfusion were measured in 159 control, preCDNF and postCDNF hearts (Figure 4 E) . As seen, while in the control hearts the 160 mean infarct area reached 42%, the hearts subjected to preCDNF or postCDNF treatments 161 showed substantial reduction in the infarct area to 19% and 25%, respectively. 162
As shown in Figure 4 (panels F-H), there was a significant reduction in the mean 163 number of ventricular arrhythmias or non-sustained tachyarrhythmia events (panel F) 164 produced during the 60 min of reperfusion in preCDNF and postCDNF protocols. The number 165 of sustained ventricular tachyarrhythmias was not significantly reduced by preCDNF or 166 postCNDF treatments (panel H), although the duration of these tachyarrhythmias was reduced 167 from ~48 s to 33 and 25 s in preCDNF and postCDNF, respectively (panel G). 168
PI3K/AKT pathway is mediating the cardioprotective effects of exoCDNF 169
Next, we examined the signaling pathway involved in the cardioprotective effect 170 conferred by exoCDNF. Surprisingly, only wortmannin was able to abrogate the 171 AG490 (JAK-STAT3 inhibitor), rottlerin and chelerythrine (PKC inhibitors) failed as 173 displayed in Figure 5 . As seen in Figure 4 , the massive recovery in LVDP (panel A) or the 174 maintenance of the low values of LEVDP (panel B) observed with preCDNF treatment before 175 I/R injury (squares) were completely abolished in the presence of wortmannin (triangles) and 176 values were similar to those of the control groups (circles). Because only wortmannin 177 abrogated CDNF-induced cardioprotection in preCDNF condition, only this inhibitor was 178 evaluated in postCDNF treatment, and again wortmannin abrogated LVDP recovery ( Figure  179 4C). The pre-treatment with wortmannin led to an increase of infarct area in preCDNF and 180 postCDNF to ~40% and ~45%, respectively, similar to the control (Figure 4E) . The lack of 181 effect of the other inhibitors on infarct area are depicted in Figure 5 . In addition, treatment 182 with wortmannin in preCDNF and postCDNF protocols abolished the reduction of ventricular 183 arrhythmias in hearts subjected to I/R (Figure 4 F and G) . Besides, as shown before in Figure  184 2, addition of wortmannin also abrogates the protective effects of CDNF on calcium transients 185 after TG addition. 186
The levels of phosphorylated AKT (p-Akt) were evaluated in hiPSC-dCM, mouse 187 cardiomyocytes and isolated hearts before and after addition of exoCDNF (Figure 6 , panels 188 A, B and C, respectively). In all three models, the levels of p-Akt more than doubled after 189 CDNF addition, except when CDNF was added after incubation with wortmannin. 190
exoCDNF exerts a protective effect on mitochondrial function after heart I/R 191
Protection of mitochondrial function during I/R has been reported to be beneficial to 192 cardiomyocytes (Heusch, 2015) . In order to investigate whether CDNF could exert any effect 193 on mitochondrial function and whether wortmannin could counteract these effects, 194 mitochondria were isolated from hearts subjected to I/R in the Langendorff model with or 195 without perfusion of CDNF (preCDNF or postCDNF) and CDNF+Wortmannin (Figure 7) . 196
As expected, ADP-stimulated complex I respiration was reduced in the I/R group and 197 this decrease was restored partially, but significantly, by pre or postCDNF treatments 198 (1mol/L); but the pre-treatment was more effective (panel A). Wortmannin abrogated the 199 improvement conferred by preCDNF and postCDNF. The same scenario was found for ATP 200 production (panels C and D) and mitochondrial swelling (panels E and F), indicating that the 201 I/R-induced oxidative phosphorylation impairment and the increased mitochondrial volume 202 were partially reversed by pre or postCDNF treatments, acting through the PI3K/AKT 203 pathway. Mitochondrial complex IV respiration and maximal oxygen uptake of uncoupled 204 mitochondria were not different between groups, reflecting an equal loading of viable 205 mitochondria (panel B). Mitochondrial transmembrane potential (Δψ) showed an increase due 206 to I/R, reflecting the inner transmembrane depolarization. PreCDNF and postCDNF treatments 207 ameliorated this dangerous Δψ increase and wortmannin abrogated the beneficial effects of 208 CDNF (panels G and H, respectively). Next, mitochondrial ROS production was measured 209 and, as expected, I/R led to an enhancement in ROS levels, but pre or postCDNF treatments 210 reduced ROS only when wortmannin was absent (panels I and J, respectively). 211
To test whether exoCDNF could exert a direct mitochondrial protection independent 212 of PI3K/AKT activation, mitochondria from non-ischemic hearts were isolated and subjected 213 to hypoxia/reoxygenation with or without previous incubation with CDNF. As shown in 214 Figure 8A , the ADP-stimulated complex I respiration was reduced in hypoxia/reoxygenation 215 group compared to control group, but in this case CDNF was ineffective in blocking or 216 reversing this effect, confirming that intact cells are necessary for the beneficial effects of 217 CDNF. Mitochondrial complex IV respiration and maximal oxygen uptake of uncoupled 218 mitochondria were not different between groups, reflecting an equal loading of viable 219 mitochondria ( Figure 8B) . 220
KDEL-R in the membrane binds CDNF and mediates its cardioprotective activity 221
We postulated that KDEL-R, which has been found in the cell membrane (Henderson 222 et al., 2013; Becker et al., 2016; Ruggiero et al., 2017) and has on its operator sequence an ER 223 stress-responsive element (ERSE) (Mizobuchi et al., 2007; Oh-Hashi et al., 2013) , might 224 function as a CDNF receptor. To investigate this, we perfused hearts before CDNF treatment 225 with two heptapeptides, which incorporate the last seven amino-acid residues of human 226 (THPKTEL) and rat (TRPQTEL) CDNF. The rationale was to block CDNF's putative 227 binding site on the KDEL-R, thus impairing CDNF function. As seen in Figure 9 , 228 (TRPQTEL, panels A-C and THPKTEL, panels D-F), both peptides were able to prevent 229 the cardioprotection induced by preCDNF treatment, abolishing the beneficial recovery of 230 LVDP (panels A and D, diamonds), the beneficial reduction of LVEDP (panels B and E, 231 diamonds), and the decrease in infarct areas of the hearts (panels C and F) induced by 232 CDNF. As seen in these panels, perfusion with the peptides alone was not able to confer 233 cardioprotection (triangles in all panels), suggesting that the occupancy of the binding site on 234 cardioprotection. 236 Cardiomyokines are proteins secreted by a healthy or a diseased heart displaying a 249 beneficial autocrine/paracrine function Doroudgar and Glembotski, 250 2011; Maciel et al., 2017) . The present study is the first to characterize CDNF as an effective 251 cardiomyokine that protects whole hearts, mice and especially human cardiomyocytes (iPS 252 derived) in culture against injuries provoked by calcium overload, specifically, in our study, 253 I/R and TG. As shown by others, MANF has cardioprotective activity (Tadimalla et al., 2008; 254 Glembotski et al., 2012 ) and here we have extended this concept to CDNF, conferring on this 255 member of this unusual family of neurotrophic factors a cardioprotective activity as well. 256
Thus, CDNF and MANF can be considered as neuro/cardiokines and it is possible that other 257 beneficial effects will be described in the near future for this interesting family of proteins. In 258 fact, it has been shown that MANF and CDNF are also important regulators of inflammation 259 and tissue repair (Neves et al., 2016; Sousa-Victor et al., 2018) . The exacerbated production of 260 pro-inflammatory mediators is well known for the deleterious effects, leading to chronic tissue 261 injury (Nishida et al., 2017; Sousa-Victor et al., 2018) . 262
What is the commonality of all these actions of CDNF and MANF? All the processes 263 in which CDNF and MANF are involved, including neuro and cardioprotection, modulation of 264 inflammation, homeostasis of pancreatic -cells (Hummasti et al., 2010; Lindahl et al., 2014) , 265 among others, have ER-stress as their underlying cause. Interestingly, both proteins are ER-266 resident proteins, but differently from other ER/SR-resident stress-related proteins, their 267 expression is enhanced upon ER/SR-induced stress, and more importantly they are secreted to 268 the extracellular milieu to exert beneficial functions in neighboring cells. Thus, this new 269 family of neuro/cardiotrophic factors has an intracellular activity, not yet completely 270 understood, as well as extracellular functions that endow this new group of proteins with 271 potential applications in medicine. 272
It has been shown that MANF expression and secretion also increase when rat 273 cardiomyocytes (and HeLa cells) are treated with TG, but not with tunicamycin or DTT, other 274 ER/SR-stressors that do not alter calcium homeostasis, leading to the proposition that MANF 275 is retained in the ER/SR through a calcium-dependent mechanism, which relies on GRP78 276 forming a complex with MANF only in the presence of this ion (Glembotski et al., 2012) . 277
Once calcium concentration in the ER/SR is decreased (under stress conditions), the complex 278 could dissociate leading to MANF secretion allowing its action as a cardiomyokine. Although 279 MANF has a KDEL-like sequence (RTDL) in its C-terminal end, this degenerated sequence 280 has a decreased affinity for the KDEL-R (Glembotski et al., 2012; Henderson et al., 2013 ) 281 favoring its unbinding and secretion. The data presented here suggest that a similar mechanism 282 of secretion might operate for CDNF in cardiomyocytes, although we did not investigate this 283 deeply. Our main focus here was to discover how CDNF exerts its paracrine/autocrine 284 functions in the cardiac context once the protein is secreted in response to an ER/SR insult. 285
Our data showed that heart hemodynamic function was significantly preserved upon 286 CDNF treatment under pre-or post-conditioning regimens. We also showed that ventricular 287 arrhythmias were significantly reduced by CDNF, as was infarct area (Figure 4) . Interestingly, 288 all these cardioprotective effects conferred by CDNF were abrogated when its interaction with 289 the KDEL-R was blocked (Figures 9 and 11) . We thus were able to identify the KDEL-R as a 290 putative receptor for this neuro/cardiokine family of proteins, and PI3K/AKT as the signaling 291 pathway that is activated upon receptor binding, at least for CDNF in the heart (Figures 2, 4 , 6 292 and 7). 293
The KDEL receptor is a seven-transmembrane-domain protein whose function is to 294 sort and retrieve proteins bearing a KDEL sequence (calnexin, GRP78, PDI, for instance) and 295 possibly proteins with KDEL-like sequences (Erp72, MANF and CDNF) from the Golgi 296 complex to the ER/SR (Dorner et al., 1990; Voutilainen et al., 2015; Becker et al., 2016) . The 297 importance of KDEL-R to cardiomyocyte homeostasis was demonstrated by studying 298 transgenic mice that express a mutant KDEL-R in which reverse transport from Golgi to 299 ER/SR was compromised. These animals die after birth with cardiac hypertrophy (Hamada et 300 al., 2004) . Recent studies, however, have suggested that the KDEL-R has additional functions 301 and new cellular localizations, including the plasma membrane. In this regard, there is 302 mounting evidence for the presence of KDEL-R at the surface of mammalian cells, where the 303 receptor binds cargo proteins such as A/B microbial toxins K28, MANF and other proteins in 304 which a KDEL-sequence is present at the C-terminus (Riffer et al., 2002; Henderson et al., 305 2013; Becker et al., 2016; Trychta et al., 2018) . Trychta and collaborators (2018) have coined 306 the term "ER exodosis" in an elegant study where they showed a massive departure of proteins 307 containing KDEL-related sequences upon calcium-induced ER-stress in several mammalian 308 cell lines. Even beneficial chaperones were among the proteins that were released. 309
The importance of the KDEL-R for MANF trafficking has been investigated in SH-310 SY5Y cells by using cells expressing different MANF constructs (with or without the RTDL 311 sequence) in combination with different isoforms of the KDEL-R (KDEL-R1, 2 and 3) 312 (Henderson et al., 2013) . Interestingly, that study showed consistently that removal of the C-313
terminal RTDL sequence of MANF increased its secretion, reinforcing the idea that KDEL-R 314
is an important partner of MANF in ER, although other studies questioned this interpretation 315 (Norisada et al., 2016) . Besides, the study conducted by Henderson and collaborators 316 (Henderson et al., 2013) detected the presence of FLAG-tagged KDEL-R at the cell surface 317 under ER-stress, and MANF binding to the cell surface required the RTDL sequence. This 318 study unequivocally showed that KDEL-R located at the cell membrane modulates the binding 319 of extracellular MANF, leading to the conclusion, as posed here, that the KDEL-R is the 320 putative receptor for this family of NFs. Unfortunately, that study did not relate MANF-321 induced cardioprotection with its binding to cell membrane KDEL-R, a relation that we have 322
shown here for CDNF, since the blockade of KDEL-R by peptides or the occlusion of KTEL 323 sequence of CDNF by the antibody anti-CDNF abrogated the beneficial effects of CDNF on 324 hearts and cardiomyocytes (Figures 9 and 11) . Thus, the second novelty of the present study 325 was to show that CDNF exerts its cardioprotective activity through binding to the KDEL-R 326 that resides at the cell membrane, whose concentration increases upon ER/SR-stress (Becker et 327 al., 2016) . It is also important to note that the interaction with KDEL-R is pH dependent, being 328 stronger at acidic pH (Wilson et al., 1993) . Acidification occurs in ischemia, supporting the 329 notion that MANF or CDNF interaction with KDEL-R at the cell membrane might be even 330 stronger under ischemia. 331
For MANF, a recent study identified that the sulfoglycolipid sulfatide present in the 332 outer cell-membrane leaflet plays a fundamental role in MANF internalization and 333 cytoprotection in C. elegans and mammalian cells (Bai et al., 2018) . CDNF did not require 334 this sulfatide for its cellular internalization, but CDNF was not deeply explored in that study. 335
Indeed, the N-domain of MANF and CDNF has a saposin-like fold, suggesting its direct 336 interaction with membrane lipids without the necessity of a receptor. Our data, however, 337 identified KDEL-R as a putative receptor for CDNF in the heart. How can we reconcile these 338 observations? Calcium-induced ER/SR-stress increases the secretion of MANF and CDNF 339 (and also other ER/SR-resident proteins), [Figure 1 and ( Bai et al., 2018) ] to the extracellular 340 milieu. ER-stress also enhances the expression of KDEL-R through the action of the 341 transcription factor XBP1 (Trychta et al., 2018) , increasing the presence of KDEL-R at the 342 cell membrane (Henderson et al., 2013) . Outside the cells, MANF and CDNF would establish 343 an initial "unspecific" contact (mediated by sulfatide in the case of MANF) with the lipid 344 bilayer through its N-domain and a further specific interaction with newly arrived KDEL-R 345 through its C-terminal domain. Currently, we do not know whether the KDEL-R bound to 346 CDNF is internalized and if so, what would be their fate. However, as presented here, 347 CDNF/KDEL-R activates PI3K/AKT signaling. We do not know what is(are) the connector(s) 348 between CDNF/KDEL-R and PI3K/AKT signaling, but we do know that the increase in p-349
AKT that takes place in hearts upon CDNF treatment is abrogated by THPKTEL, a peptide 350 that binds to the KDEL-R at the cell membrane, but not by DRATSAL, a scrambled, 351 ineffective peptide (Figure 6D and Figure 10) . 352
There are several reports in the literature showing signaling pathways controlled by 353 KDEL-R mainly in cancer or neuronal cells. Interestingly, GRP78, which is present at the cell 354 membrane in several cancer cells, co-localizes with both subunits of PI3K, namely p85 and 355 p110, as well as with PIP3 controlling PI3K/AKT pathway either directly or indirectly (Zhang 356 et al., 2013) . We are currently conducting additional experiments to dissect these missing 357
connections. 358
Cardiac ischemia induces calcium transient depletion resulting in the halting of the 359 contractile machinery and cell injury (Heusch, 2015) . Immediate restoration of blood flow 360 (reperfusion) is essential for myocardial survival, however, paradoxically, reperfusion itself 361 can induces injury mediated by ER/SR stress, cytosolic calcium overload and mitochondrial 362 impairment (Heusch, 2015) . We have shown that CDNF prevents ER/SR-stress, by recovering 363 calcium transient from cardiomyocytes. This effect would reduce calcium overload and 364 prevent mitochondrial lesions and cell death (Heusch, 2015) . Additionally, the treatment with 365 CDNF prevents lesions by I/R. Similar results were observed with MANF (Glembotski et al., 366 2012) , showing infarct size reduction in mice hearts. Indeed, CDNF reduces cerebral ischemic 367 lesions by ER/SR-stress prevention (Zhang et al., 2018) . Curiously, in our study, CDNF was 368 able to prevent myocardial injury, not only in pre-ischemic treatment, but also in post-369 ischemic treatment. Since CDNF reduced reversible and irreversible I/R injuries, it could be a 370 potential treatment against revascularization lesions. However, despite experimental studies 371 having shown that interventions during myocardial reperfusion can reduce myocardial infarct 372 size by up to 50%, clinical studies that use these strategies have not been successful (Yellon 373 and Hausenloy, 2007) . Thus, there is a necessity to develop new therapies against I/R injury. 374
The Reperfusion Injury Salvage Kinase (RISK) pathway has emerged as a new target for 375 preventing lethal reperfusion injury. There is a consensus, that the RISK pathway mediates the 376 programmed cell survival, as well as an extensive preclinical evidence that activation of this 377 pathway by pharmacological agents reduces the size of myocardial infarction by up to 50% 378 (Hausenloy and Yellon, 2004) . Cardioprotection by RISK pathway has been attributed to the 379 activation of PI3K/AKT signaling pathway inducing inhibition of mitochondrial mPTP 380 opening, sarcoplasmic reticulum Ca 2+ uptake improvement, and antiapoptotic pathway 381 activation (Yellon and Hausenloy, 2007; Heusch, 2015) . These kinases are activated during 382 myocardial reperfusion and confer cardioprotection avoiding lethal reperfusion injury 383 (Hausenloy and Yellon, 2004) . As shown in the present study, wortmannin, was the only 384 tested inhibitor that was able to abrogate all the beneficial effects of CDNF. Altogether, these 385 data unequivocally point to PI3K/AKT signaling as responsible for the cardiomyokine activity 386 of CDNF. This was confirmed by increased levels of p-AKT after exogenous CDNF and 387 return to basal levels in the presence of CDNF plus wortmannin. Interestingly, THPKTEL also 388 reversed the increase in p-AKT levels induced by CDNF, connecting the binding of CDNF to 389 the KDEL-R to PI3K/AKT activation. 390
In conclusion, the present study characterizes CDNF as new cardiomyokine acting at 391 the cell membrane through its putative receptor KDEL-R and activating PI3K/AKT to exert its 392 cardioprotective activity. All these findings are summarized as a model in Figure 12 . 393 394 All solutions were freshly prepared using MilliQ® Water or high quality analytical 396 grade organic solvents. All solutions were filtered before the use. The chemicals were obtained 397 from Sigma-Aldrich (St. Louis, MO, USA) or purchased from vendors as indicated. 398
CDNF production and purification 399
The plasmid pET-25b(+) containing a synthetic CDNF cDNA was transformed into 400
Escherichia coli strain Rosetta Gami B (DE3) (Stratagene, San Diego, California, USA). Cell 401 cultures were grown at 37°C and induced with 1mmol/L IPTG for 2h. The cells were 402 harvested by centrifugation, resuspended in extraction buffer (20mmol/L MES at pH 6.0, 403
Complete, EDTA-free Tabs-Roche, Basel, Switzerland) and lysed by sonication at 4°C. 404
After centrifugation, the fraction containing the soluble proteins was loaded onto a 5mL Hitrap Use Committee (100/16 and 015/17). 416
Differentiation of human induced pluripotent stem cells into cardiomyocytes 417
Human induced pluripotent stem cells (hiPSCs) were differentiated into cardiac 418 lineage following 30 days of induction as previously described (Lian et al., 2013) . Briefly, 419 3x10 5 hiPSCs were plated on 48 plate dish treated with 1% of Matrigel® hESC-Qualified 420 Matrix (Corning™, New York, USA) and cultivated on 2mTeSR™1 (STEMCELL 421
Technologies, Vancouver, Canada) for 3 days. On day 0, the cells were cultivated in RPMI 422 1640 (Gibco™, Thermo Fisher, Waltham, Massachusetts, USA) supplemented with B-27™ 423 (1640 (Gibco™) Supplement, without insulin (Gibco™) (RB-) and 9 μmol/L of CHIR 99021 424 (R&D SYSTEMS, Minneapolis, Minnesota, USA). After 24h, the cells were cultivated with 425 RB-for the next 2 days and on day 3 and 4, the WNT signaling was inhibited with 10 and 5 426 areas and the cells were then cultivated in RPMI 1640 (Gibco™) supplemented with B-27™ 428 Supplement (Gibco™) (RB+) until day 30 th . These cells were called hiPSC-dCM (Human 429 induced pluripotent stem cells differentiated into cardiomyocytes). 430
For efficiency evaluation of cardiomyocyte differentiation, after day 30, the hiPSC-431 dCM was dissociated using Tryple 1x (Gibco™) until the cells detached from the culture 432 plate. Then the cells were centrifuged at 300g/5min. The cells were fixed with formaldehyde 4 433 % for 20 min at room temperature, permeabilized with PBS Triton 0.3 % for 30 min and 434 stained with Troponin T (1:200) (Thermo Fisher) for 30 min AT 4ºC. Afterwards the cells 435
were stained with Alexa Fluor 647 goat anti mouse IgG (1:1,000) secondary antibody (Thermo 436
Fisher) for 30 min at 4ºC. The cells stained only with secondary antibody were used as 437 fluorescence negative control. The data was acquired by BD Accuri™ C6 (BD Biosciences, 438
San Jose, CA, USA) and analyzed with the FlowJo v10.1 software (FlowJo, USA). 439
Isolation and culture of mice cardiomyocytes 440
The cardiomyocytes were isolated from hearts of neonatal mice (CD1-black) 1-3 days 441 after birth. Briefly, the hearts were dissected out, placed in PBS and washed. The heart tissue 442 was minced and digested in a dissociation solution (In mol/L: NaCl, 136.7; KCl, 2.68; 443 Na2HPO4, 0.352; NaHCO3, 11.9; dextrose, 11) containing pancreatin (1.25mg/ml; Sigma-444 Aldrich) and bovine serum albumin (BSA; 3 mg/mL; Sigma-Aldrich) for 5 min at 37°C with 445 gentle stirring. The supernatant fraction containing cells from each digestion was collected in a 446 conical tube, suspended in growth medium containing 15% fetal bovine serum for inhibition 447 of proteolytic enzymes and spun at 300 g/5 min. Elimination of non-muscle cells was achieved 448 by pre-plating for 1h. After that, the cells were counted and seeded in 6-well plates at a density 449 of 10 5 cells/well and cultured in DMEM-high glucose containing 10% FBS at 37°C and 5 % 450 CO2. Experimental in-vitro conditions were established 3 days after plating (Bagno et al., 451 2016) . 452
Immunocytochemistry imaging and quantification of fluorescence intensity 453
Cells were fixed with 4% paraformaldehyde for 10 min at room temperature. Then, 454 cells were permeabilized in 0.3% triton X-100 in PBS and incubated with blocking solution 455 (5% BSA, in PBS pH 7.4) for 1h. After incubation with appropriate primary (1:500), 456 secondary antibodies (1:500) and Hoechst (1:5,000) cover slips were mounted with prolong. 457
Images were acquired with an Olympus DS-Fi2 confocal microscope equipped with 63x oil 458 immersion objective and with a Nikon DS-fi2 camera operated with the standard QC capture 459 using the corrected total cell fluorescence (CTCF) method. 461
Obtention of media and cell sample extracts 462
Cell media without fetal bovine serum were collected, appropriately concentrated, 463 boiled and combined with the Laemmli sample buffer before SDS-PAGE and Western blot. 464
The cells lysates were obtained by extracting cells in a minimal volume of cell lysis buffer 465 composed of RIPA buffer (Sigma-Aldrich), EDTA 50 mmol/L (pH 8.0), sodium fluoride 5 466 mmol/L, 10% SDS, protease inhibitor mixture (Roche), phosphatase inhibitor mixture 1 467 (Sigma Aldrich) phosphatase inhibitor mixture (Sigma Aldrich). Samples of the media 468 samples (150 µg) and cell extracts (50 µg) were analysed by SDS-PAGE, followed by 469
Western blot. 470
[Ca 2+ ] Measurements 471
Human iPSC-dCM were plated on glass coverslips for 5 days and loaded with 5 472 μmol/L Fura-2AM at 37 °C in complete culture medium containing 2.5 mmol/L probenecid 473 for 40-60 min before the intracellular calcium measurements. The cells were then 474 accommodated in a chamber whose base was formed by the coverslip containing the cells that 475 were maintained at 37 °C in the complete medium (volume of the incubation chamber -500 476 μL). Cytoplasmic calcium concentrations of groups of hiPSC-dCM (20-30 cells) were 477 measured on a fluorescence imaging spectrofluorimeter (Easy Ratio Pro equipped with a 478
DeltaRAMX Illuminator, an Olympus IX71 microscope, a QuantEM 5125C camera and the 479 Image-Pro Plus v 6.3 software; PTI Photon Technology International, Princeton, NJ). Fura-2 480 was excited alternately at 340 nm and 380 nm, and the emission was collected at 510 nm. The 481 ratio measurement, which is proportional to the cytoplasmic calcium concentration, was 482 determined every 100 ms for at least 5 min. Free intracellular Ca 2+ concentration [Ca2+]i was 483 monitored in arbitrary units as the F340/380 nm ratio. The amplitude of variations in [Ca 2+ ]i (∆ 484 F340/F380) for cells without treatment and with treatment were obtained for 5 different 485 intervals of 5-10 seconds from ratio measurements. 486 were incubated with wortmannin (0.3 µmol/L) for 20h before the calcium measurements. The 503 media was not changed after each substance addition in each group. The calcium 504 measurements and/or Western blot analyses were performed after 20h of incubation in all 505 groups. 506
Treatments applied to hiPSC-dCM and mouse cardiomyocytes before Western blot and

Langendorff experimental protocols and I/R 507
The I/R experiments were performed on isolated rat hearts as described previously 508 (Maciel et al., 2017) . The hearts were rapidly removed and cannulated through the aorta in a 509 modified Langendorff apparatus and perfused at constant flow of 10 mL/min with Krebs-510
Henseleit buffer (KHB) solution: in mmol/L -NaCl 118; NaHCO3 25; KCl 4.7; KH2PO4 1.2; 511 MgSO4 1.2; CaCl2 1.25, and glucose 11, at 37°C and equilibrated with a gas mixture of 95% 512 O2 and 5% CO2 (pH 7.4). The perfusion temperature was held constant by a heat exchanger 513 located next to the aortic cannula. A fluid-filled latex balloon was inserted through the left 514 atrium into the left ventricle and connected to a pressure transducer and the PowerLab System 515 (AD Instruments, Australia) for continuous left ventricular pressure recording. The left 516 ventricular end-diastolic pressure (LVEDP) was set to 10mmHg by balloon inflation; during 517 the experiment, the hearts were continuously immersed in 37°C warm buffer to avoid 518 hypothermia. Hearts were allowed to stabilize for 20 min before a protocol was started. All 519 hearts were submitted to 30min of basal recordings. The ischemia protocol was induced by full 520 stop of retrograde perfusion during 30min. The reperfusion was performed by full re-521 establishment of retrograde perfusion during 10min for mitochondria analysis or 60min for 522 infarct size measurements. Langendorff experimental protocols: Conditions/Groups: No-I/R: 523
Hearts were perfused with KHB solution for 90min (only for mitochondria isolation); I/R: 524 min of reperfusion with KHB solution; CDNF-preconditioning: The hearts were perfused 526 with the KHB containing CDNF (1 µmol/L) for 5min before 30min of global ischemia 527 followed by 10 or 60 min of reperfusion with KHB. In the groups with antagonist, the 528 substances were perfused for 5min before CDNF and along with CDNF (1 µmol/L) for 5min.; 529 CDNF-postconditioning: Global ischemia was induced for 30 min by full stop of retrograde 530 perfusion followed by the perfusion with KHB plus CDNF (1 µmol/L) during the first 5 min, 531 followed by 5 or 55 min of reperfusion with KHB without CDNF. The antagonists used in the 532 present study were: Wortmannin 0.3 µmol/L (PI3K-AKT inhibitor), Chelerythrine 10 µmol/L 533 and Rottlerin 10 µmol/L (PKC inhibitors), and AG490 10 µmol/L (JAK-STAT3 inhibitor). 534
The samples of isolated hearts were collected after 60min of reperfusion for Western-blot 535 analyzes. 536
Left ventricular developed pressure (LVDP), left ventricular end-diastolic pressure 537 (LVEDP) and infarcted area measurements 538
LVDP and LVEDP were analysed at different time points during the experiments, 539 namely, at baseline, every 5 min during ischemia, and every 5min during reperfusion until 540 60min of reperfusion. For this, the mean value of a 30 sec recording at the respective time 541 point was taken. After 60 min reperfusion period, the hearts were sliced into 1.5 mm cross-542 sections from apex to base and incubated in 1% triphenyl tetrazolium chloride (TTC) for 4 min 543 at 37 °C, followed by incubation in a 10% (v/v) formaldehyde solution for 24h to improve the 544 contrast between the stained (viable) and unstained (necrotic) tissues. The infarct area was 545 determined by planimetry using ImageJ software (version 1.22, National Institute of Health, 546 USA). Infarct size was expressed as a percentage of the area at risk (total). 547
ECG recordings in isolated hearts 548
Three silver-silver chloride electrodes were used to obtain electrocardiographic 549 recordings. Two electrodes were connected to the differential input of a high-gain amplifier 550 (BioAmp; AD Instruments) positioned close to the left ventricle and right atrium. The third 551 electrode was grounded. The electrocardiograms were recorded with PowerLab/400 and Chart 552 4.0 software (AD Instruments). 553
Peptides used in I/R experiments 554
The peptide sequences corresponding to the last 7 amino-acid residues of the C-555 terminal region from human (THPKTEL) and rat (TRPQTEL) CDNF or a scrambled peptide 556 purity. In the experiments where the peptides were tested separately, each peptide at 2 µmol/L 558 was perfused during 5 min before I/R. When the peptides were tested in combination with 559 CDNF, they were first perfused alone (2 µmol/L) and then together with CDNF (1 µmol/L) for 560 5 min before I/R 561
Antibody used in I/R experiments 562
To reinforce the evidence that the KDEL receptor is involved in the protection 563 induced by CDNF, 5 µg/ml of the antibody (Sigma Aldrich, St. Louis, MO) against peptides 564 from the C-terminal domain of human CDNF were incubated with CDNF 1 µmol/L during 1 h 565 before the experiment. After 1h of incubation, CDNF (1 µmol/L) plus the antibody (5µg/ml) 566
were perfused for 5 min before the ischemia and reperfusion protocol. 567
Western blots 568
SDS-PAGE gels were transferred to PVDF membranes. The membranes were probed 569 with the following antibodies: CDNF (Sigma Aldrich; 1:1,000), GAPDH (Santa Cruz 570 Biotechnology; 1: 10,000, Santa Cruz, CA, USA), GRP78 (Santa Cruz Biotechnology; 571 1:1,000), CHOP (Santa Cruz Biotechnology; 1:500), p-AKT (Cell Signalling; 1:750, Danvers, 572 MA, USA), total AKT (Cell Signalling; 1:750), GRP78 (Sigma Aldrich; 1:1,000). 573
Mitochondria isolation and measurements of mitochondrial function 574
Mitochondria isolation was performed according to (Gedik et al., 2017) . After 10 min 575 of reperfusion, the isolated hearts were rapidly removed, placed in ice-cold isolation buffer 576 containing, in mmol/L: 250 sucrose, 10 HEPES, 1 ethylene glycol tetra acetic acid (EGTA), 577 pH 7.4 with 0.5% w/v bovine serum albumin (BSA), minced thoroughly using scissors, and 578 then homogenized with a tissue homogenizer (Ultra-Turrax) using two 10 sec treatments at a 579 shaft rotation rate of 6,500 rpm to release subsarcolemmal mitochondria. This homogenate 580 was further homogenized with proteinase type XXIV (8 IU/mg tissue weight, Sigma Aldrich) 581 using a Teflon pestle for the release of the interfibrillar mitochondria from the tissue. The 582 homogenate was centrifuged at 700g for 10 min at 4°C. The supernatant was collected and 583 centrifuged at 12,000g for 10min. The resulting pellet was resuspended in isolation buffer 584 without BSA and centrifuged at 10,000 g for min at 4°C. This procedure was repeated, and the 585 pellet was resuspended in isolation buffer. The protein concentration of the isolated pellet was 586 determined using a protein assay (Lowry method, Biorad, Hercules, CA, USA) by comparison 587 to a BSA standard (Thermo Scientific, Waltham, MA, USA). 588 respiration measurement was determined immediately and compared with ATP standards 621 using a 96-well white plate and a spectrofluorometer SpectraMax® M3 (Molecular Devices 622 California, EUA) at 560 nm emission (Gedik et al., 2017) . 623
Mitochondrial swelling and transmembrane potential measurements 624
The mitochondrial swelling and mitochondrial transmembrane potential were 625 evaluated using a high resolution spectrofluorometer SpectraMax® M3 (Molecular Devices 626
California, EUA). The integrity of the mitochondrial membrane was assessed by varying the 627 osmotic volumes of the mitochondria by spectrophotometric determination of the apparent 628 absorption of the suspension at 540 nm. A mitochondrial suspension (100 μg/mL) was added 629 to the breathing medium in the absence of respiratory substrates at 37 ° C and under constant 630 stirring. The mitochondrial turgor was stimulated with 100 nmol/L of calcium. The swelling 631 was expressed as a percentage of the absorption of the solution containing mitochondria in the 632 presence of Ciclosporin A (0% swelling), in relation to the light emitted after the addition of 633 FCCP 1µmol/L (100% swelling). For mitochondrial transmembrane potential (Δψ) 634 determination, the probe TMRM (tetramethylrhodamine methyl ester, 400 nmol/L) was added 635 to the incubator solution containing 100 μg/ml of mitochondria for 1h. The Δψ was estimated 636 by the fluorescence emitted by TMRM under excitation of 580 nm. The Δψ was expressed as 637 the percentage of fluorescence emitted by TMRM when mitochondria were incubated in the 638 presence of cyclosporin A (0% Δψ), relative to the fluorescence emitted after addition of 639 FCCP to fully depolarized mitochondria (100% Δψ). 640
Extramitochondrial ROS concentration measurements 641
The Amplex Red Hydrogen Peroxide Assay (Life Technologies, Carlsbad, CA, USA) 642 was used to determine extramitochondrial ROS concentration. Amplex Red reacts in 1:1 643 stoichiometry with peroxide in the presence of horseradish peroxidase (HRP) and produces 644 highly fluorescent resorufin. The incubation buffer containing mitochondria was removed 645 from the respiration chamber, and immediately supplemented with 50 µmol/L Amplex 646
UltraRed and U/mL HRP. The supernatant was collected after 120 min of incubation in the 647 dark. Extramitochondrial ROS concentration was determined and compared with H2O2 648 standards using a 96-well black plate and a spectrofluorometer SpectraMax® M3 (Molecular 649
Devices California, EUA) at 540 nm emission and 580 nm extinction wavelengths (Gedik et al., 650 2017) . 651
Statistics 652
analysed by one-way ANOVA. When a significant difference was detected, one-way ANOVA 654 was followed by Bonferroni post-hoc tests (GraphPad Prisma 6.0 software, San Diego, 655
California, USA). 656 10. 1016/j.expneurol.2010.12.013. 819 
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